Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
庫利南腫瘤學公司(納斯達克代碼:CGEM-GET Rating)的股價週三在交易前大幅上漲。該股此前收於12.76美元,但開盤報13.60美元。庫利南腫瘤學的股票最新報12.84美元,成交量為148股。
Cullinan Oncology Stock Down 3.3 %
庫利南腫瘤學股票下跌3.3%
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
該公司市值為5.4734億美元,市盈率為5.40倍,貝塔係數為-0.09。該業務的50日移動均線切入位為12.64美元,200日移動均線切入位為12.65美元。
Insiders Place Their Bets
內部人士下注
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
在庫利南腫瘤學的其他新聞中,內部人士詹妮弗·邁克爾森在9月27日星期二的一筆交易中出售了4000股該公司的股票。這些股票以12.40美元的平均價格出售,總成交額為49,600.00美元。出售後,這位內部人士現在擁有該公司53,031股,價值約657,584.40美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。7.50%的股份由公司內部人士持有。
Institutional Investors Weigh In On Cullinan Oncology
機構投資者參與庫利南腫瘤學
Cullinan Oncology Company Profile
庫利南腫瘤學公司簡介
(Get Rating)
(獲取評級)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
庫利南腫瘤公司是一家生物製藥公司,專注於為美國的癌症患者開發一系列靶向腫瘤學和免疫腫瘤學療法。該公司的主要候選藥物是CLN-081,這是一種口服小分子藥物,正在進行I/IIa期劑量升級和擴大試驗,用於治療非小細胞肺癌患者。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免費獲取StockNews.com關於庫利南腫瘤學的研究報告(CGEM)
- Verra移動庫存已返回空間站
- ASML的11月拉力賽有後勁嗎?
- 在盈利暴跌後,Advance Auto Parts是一筆買入嗎?
- BJ‘s批發俱樂部:當心賣方
- 馬倫汽車股票的下一個催化劑是12月23日
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受庫利南腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對庫利南腫瘤學和相關公司的最新新聞和分析師評級的每日簡明摘要。